NovoSeven (recombinant factor VIIa) in centeral nervous systems bleeds.
Data is presented from two compassionate-use clinical trials using recombinant factor VIIa (rFVIIa) to treat central nervous system haemorrhage in 18 haemophilia A and B patients with inhibitors, and in 3 patients with FVII deficiency. Prior to rFVIIa treatment 78% of the haemophilia patients had inhibitor titres greater than 10 Bethesda units/ml. Sixty-two percent of the bleeding episodes were treated with a mean dose of 80-100 mu g/kg of rFVIIa administered repeatedly until cessation of bleeding. The overall efficacy was 84% with only one fatality and there were no major adverse events or laboratory indicators of disseminated intravascular coagulation.
Rice
K M
KM
Haemophilia Reference Centre, St. Thomas' Hospital, London, UK.
Savidge
G F
GF
D000293:Adolescent; D000328:Adult; D002493:Central Nervous System Diseases / Q000188:drug therapy* / Q000209:etiology; D002648:Child; D002675:Child, Preschool; D015942:Factor VIIa / Q000627:therapeutic use*; D006467:Hemophilia A / Q000150:complications / Q000188:drug therapy*; D006470:Hemorrhage / Q000188:drug therapy* / Q000209:etiology; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008875:Middle Aged; D011994:Recombinant Proteins / Q000627:therapeutic use
D011994:Recombinant Proteins; D015942:Factor VIIa